We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $3.89B
1-Year Est. Return 201.1%
This Fund
S&P 500
This Quarter Est. Return
-3.63%
1 Year Est. Return
+201.1%
3 Year Est. Return
+879.31%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$2.14B
AUM Growth
-$232M
Cap. Flow
-$62.6M
Cap. Flow %
-2.93%
Top 10 Hldgs %
61.97%
Holding
57
New
7
Increased
13
Reduced
4
Closed
8

Top Buys

1
ERAS icon
Erasca
ERAS
+$35M
2
IRON icon
Disc Medicine
IRON
+$33M
3
ANAB icon
AnaptysBio
ANAB
+$29.5M
4
SVRA icon
Savara
SVRA
+$18.5M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$18.1M

Top Sells

1
ALPN
Alpine Immune Sciences Inc
ALPN
+$124M
2
APLS
Apellis Pharmaceuticals
APLS
+$52M
3
JBIO
Jade Biosciences
JBIO
+$35.6M
4
GPCR icon
Structure Therapeutics
GPCR
+$27M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$22.9M

Sector Composition

1 Healthcare 99.8%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TRVI icon
26
Trevi Therapeutics
TRVI
$2.44B
$22M 1.03%
7,381,090
– –
SLN
27
Silence Therapeutics
SLN
$494M
$21.8M 1.02%
1,148,591
– –
RARE icon
28
Ultragenyx Pharmaceutical
RARE
$2.96B
$17.5M 0.82%
+425,000
New +$18.1M
AUTL
29
Autolus Therapeutics
AUTL
$394M
$16.1M 0.75%
4,623,324
– –
CERE
30
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$16.1M 0.75%
393,000
– –
MREO
31
Mereo BioPharma
MREO
$52.3M
$15.8M 0.74%
+4,401,371
New +$14.3M
IMTX icon
32
Immatics
IMTX
$1.27B
$13.4M 0.63%
+1,152,456
New +$13M
TYRA icon
33
Tyra Biosciences
TYRA
$1.87B
$13.3M 0.62%
832,220
– –
MGNX icon
34
MacroGenics
MGNX
$257M
$12.8M 0.6%
3,010,727
+539,023
+22% +$5.25M
APLT
35
DELISTED
Applied Therapeutics
APLT
$10.7M 0.5%
2,286,135
+333,278
+17% +$1.58M
PBYI icon
36
Puma Biotechnology
PBYI
$427M
$9.98M 0.47%
3,062,558
+246,264
+9% +$1.08M
ETNB
37
DELISTED
89bio
ETNB
$8.01M 0.37%
1,000,000
– –
ELEV
38
DELISTED
Elevation Oncology
ELEV
$7.99M 0.37%
+2,958,579
New +$11.1M
COGT icon
39
Cogent Biosciences
COGT
$6.43B
$7.9M 0.37%
936,576
– –
ACAD icon
40
Acadia Pharmaceuticals
ACAD
$4.39B
$7.64M 0.36%
470,338
– –
ARVN icon
41
Arvinas
ARVN
$517M
$7.6M 0.36%
285,331
– –
ADVM
42
DELISTED
Adverum Biotechnologies
ADVM
$7.34M 0.34%
1,069,244
– –
ALLO icon
43
Allogene Therapeutics
ALLO
$604M
$6.68M 0.31%
2,867,750
– –
ANTX icon
44
AN2 Therapeutics
ANTX
$169M
$4.49M 0.21%
2,088,889
+700,000
+50% +$1.67M
NAMSW icon
45
NewAmsterdam Pharma Warrant
NAMSW
$94.6M
$4.36M 0.2%
500,333
– –
DSGN icon
46
Design Therapeutics
DSGN
$770M
$4M 0.19%
+1,195,179
New +$4.66M
IMCR icon
47
Immunocore
IMCR
$1.73B
$3.69M 0.17%
+108,762
New +$5.55M
MGX icon
48
Metagenomi Therapeutics
MGX
$47.1M
$1M 0.05%
245,692
-33,333
-12% -$229K
ACRS icon
49
Aclaris Therapeutics
ACRS
$740M
$291K 0.01%
264,377
– –
APLS
50
DELISTED
Apellis Pharmaceuticals
APLS
– –
-885,165
Closed -$52M
1
2
3

Similar funds

GAMH
Greenwoods Asset Management (HK) Hong Kong $3.88B AUM 23.82% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
CCM
Channing Capital Management Chicago, Illinois $3.91B AUM 34.32% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
AA
Alesco Advisors Pittsford, New York $3.92B AUM 15.21% 1-Year Est. Return
DACG
Donor Advised Charitable Giving San Francisco, California $3.92B AUM 59.92% 1-Year Est. Return